

A PHASE 2 STUDY OF ALISERTIB IN COMBINATION WITH ENDOCRINE THERAPY IN PATIENTS WITH HR+, HER2-NEGATIVE RECURRENT OR METASTATIC BREAST CANCER

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- diagnosis of adenocarcinoma of the breast that has reoccurred or spread to other areas of the body (metastatic) - treatment with at least two prior lines of endocrine therapy in the recurrent or metastatic setting - see link to clinicaltrials.gov for complete inclusion criteria

Exclusion Criteria:

- treatment with chemotherapy in the recurrent or metastatic setting - see link to clinicaltrials.gov for complete exclusion criteria

Conditions & Interventions

Conditions:

Cancer

Keywords:

Clinics and Surgery Center (CSC), Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer

More Information

Description: The purpose of this study is to see if the study drug, called alisertib, in combination with an 'endocrine therapy' such as anastrozole, letrozole, exemestane, tamoxifen or fulvestrant can help people with HR+, HER2-negative recurrent or metastatic breast cancer. The study will also look at how well people tolerate treatment with alisertib in combination with one of the endocrine therapies that are commonly used in clinical practice.

Study Contact: Heather Beckwith - ehno003@umn.edu

Principal Investigator: Heather Beckwith

Phase: PHASE2

IRB Number: STUDY00023538

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.